View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
July 28, 2022

China’s medical devices industry sees a rise of 6.67% in deal activity in June 2022

By Carmen

China’s medical devices industry saw a rise of 6.67% in overall deal activity during June 2022, when compared with the last 12-month average, led by AstraZeneca Zhongjin Medical Industry Fund, Cambridge Capital Group, SDIC China Merchants Investment Management, Wuyuan Capital and Yunfeng Fund L.P’s $100m venture financing of Axbio, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 32 deals worth $376.9m were announced in June 2022, compared with the 12-month average of 30 deals.

venture financing was the leading category in the month in terms of volume with 31 deals, which accounted for 96.9% of all deals.

In second place was M&A with one deals accounting for 3.1% of overall deal activity in the China’s technology industry during the month.

In terms of value of deals, venture financing was the leading deal category in China’s medical devices industry with total deals worth $375.63m, followed by M&A and deals totalled $1.29m.

China medical devices industry deals in June 2022: Top deals

The top five medical devices industry deals accounted for 63.6% of the overall value during June 2022.

The combined value of the top five medical devices deals stood at $239.88m, against the overall value of $376.9m recorded for the month.

The top five medical devices industry deals of June 2022 tracked by GlobalData were:

1) AstraZeneca Zhongjin Medical Industry Fund,Cambridge Capital Group,SDIC China Merchants Investment Management,Wuyuan Capital and Yunfeng Fund L.P $100m venture financing deal with Axbio

2) The $50m venture financing of NuProbe Global by BioTrack Capital,CICC Fund Management,CR-CP Life Science Fund,Deguan Capital,Haoreng Capital,Pappas Capital,Sequoia Capital China,Shanghai Pan Lin Asset Management and Yonghua Capital

3) Brilliance Meijing,Fengshi Capital,Galaxy Yuanhui Investment,Gandao Investment Holding Group,Junci Investment,Qiaodao Investment Fund Management (Beijing),Shengxiang Biotechnology and Wuxi Guojing Investment Management $44.98m venture financing deal with Shanghai Singlera Genomics Technologies

4) The $29.93m venture financing of Guangzhou Jiajian Medical Testing by Besen Medical Fund,CICC Qide Fund,Jiuzhoutong Venture Capital and Yueke Finance

5) Founder Securities and Tao Capital Partners $14.98m venture financing deal with Danyang Huichuang Medical Equipment

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network